The pioneer clinical studies with CCKBR-specific radiolabeled minigastrin analog [177Lu]Lu-PP-F11N demonstrated tumor-specific accumulation with low adverse reactions in MTC patients [15,16]. The gene discussed is CCKBR; the disease is neoplasm.